Announcement no. 21

Interim Financial Report for Q2 2009 for the BioPorto Group

Summary of Q2 2009

With the in-house development of a diagnostic immunoassay for use on fully automatic analysis systems, BioPorto has chosen to enter the routine diagnostics market as a direct player.In so doing, BioPorto expects to build up substantial sales of its own products which can be supplemented by the sale of licenses for other vendors’ utilization of the Group’s central NGAL cutoff patent for other types of immunoassays.

·In mid-August, BioPorto could announce a development collaboration project with one of the world’s leading companies within diagnostic analyses.The collaboration has led to the development of a homogenous NGAL immunoassay for use on fully automatic equipment at central hospital laboratories.The new NGAL immunoassay is expected to be ready for launch in the first six months of 2011.

·On August 14, the EPO processed the remarks submitted by Cincinnati Children’s Hospital, and BioPorto has been pleased to note that the EPO upholds the decision taken regarding the resumption of the issuance process as of October 1, 2009. The process had been put on hold because of a claim filed by CCH.

·By virtue of its new NGAL immunoassay for blood and urine analysis, BioPorto expects to be able to cover a large segment of the NGAL market with its own products and can therefore choose to retain some of the IP rights and thus not give up a license for use in homogeneous immunoassays.However, this does not exclude entering into licensing agreements for other areas, the possibilities of which are being evaluated.

·Revenues in the first half of 2009 rose by 17% to DKK 5.6 million (DKK 4.8 million).The revenues of the Group’s NGAL portfolio showed a very positive rise of 79%.

·BioPorto has launched a new pair of GLP-1 antibodies, a pair of Pig NGAL antibodies and, after the end of the period, a Mouse NGAL kit.

·The loss for the first six months was DKK -8.5 million (T.DKK –8.4 million).

·The board decided to increase the share capital by up to 10%.A separate announcement about this will be issued.

Expectations for the 2009 fiscal year

·BioPorto upholds its expectations for 2009 of additional growth in product sales of around 25-35% and a turnover of DKK 12-13.5 million.

·A net loss of around DKK 12 million, before possible licensing income, is still expected.

·BioPorto expects to retain some of the NGAL IP rights and, thus, not give up a license for use in homogeneous immunoassays.It is possible to enter into licensing agreements in other areas, the possibilities of which are being evaluated.